Senseonics' (SENS) "Buy" Rating Reiterated at HC Wainwright

Senseonics (NYSE:SENS - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $2.00 price objective on the stock.

Separately, StockNews.com began coverage on Senseonics in a research report on Friday, November 8th. They set a "sell" rating on the stock.

Senseonics Stock Performance

Senseonics stock traded down $0.00 during trading hours on Friday, hitting $0.28. The company had a trading volume of 6,037,480 shares, compared to its average volume of 2,884,726. Senseonics has a one year low of $0.28 and a one year high of $0.75. The firm has a 50-day moving average of $0.35 and a 200 day moving average of $0.40. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.89. The firm has a market cap of $167.18 million, a PE ratio of -2.18 and a beta of 0.79.

Institutional Investors Weigh In On Senseonics

Institutional investors have recently made changes to their positions in the stock. FMR LLC raised its holdings in Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company's stock valued at $59,000 after acquiring an additional 167,970 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new stake in Senseonics during the first quarter worth about $91,000. GSA Capital Partners LLP bought a new position in Senseonics in the third quarter valued at approximately $117,000. Virtu Financial LLC bought a new stake in shares of Senseonics during the 1st quarter worth $162,000. Finally, Symmetry Partners LLC acquired a new stake in shares of Senseonics in the 3rd quarter valued at approximately $164,000. 12.36% of the stock is currently owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.